sub:assertion {
d:DB01268 v:identifier "DB01268" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB01268" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB01268> ;
dv:drugbank-id "DB01268" , "DB07417" ;
dv:x-ahfs <
http://bio2rdf.org/ahfs:92:00.00> ;
dv:x-atc <
http://bio2rdf.org/atc:L01XE04> ;
dv:x-bindingdb <
http://bio2rdf.org/bindingdb:4814> ;
dv:x-cas <
http://bio2rdf.org/cas:557795-19-4> ;
dv:x-chebi <
http://bio2rdf.org/chebi:38940> ;
dv:x-chemspider <
http://bio2rdf.org/chemspider:4486264> ;
dv:x-dpd <
http://bio2rdf.org/dpd:2280795> ;
dv:x-kegg <
http://bio2rdf.org/kegg:D06402> ;
dv:x-ndc <
http://bio2rdf.org/ndc:0069-0550-38> ;
dv:x-pdb <
http://bio2rdf.org/pdb:B49> ;
dv:x-pharmgkb <
http://bio2rdf.org/pharmgkb:PA162372840> ;
dv:x-pubchemcompound <
http://bio2rdf.org/pubchem.compound:5329102> ;
dv:x-pubchemsubstance <
http://bio2rdf.org/pubchem.substance:46507140> ;
dv:x-wikipedia <
http://bio2rdf.org/wikipedia:Sunitinib> ;
dct:description "Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3."@en ;
dct:identifier "drugbank:DB01268" ;
dct:title "Sunitinib"@en ;
a dv:Drug ;
rdfs:label "Sunitinib [drugbank:DB01268]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB01268> , <
http://www.drugs.com/cdi/sunitinib.html> , <
http://www.rxlist.com/cgi/generic/sutent.htm> .
}